Resumen de acción EW
Edwards Lifesciences Corporation ofrece productos y tecnologías para cardiopatías estructurales y monitorización de cuidados críticos en Estados Unidos, Europa, Japón e internacionalmente.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
Competidores de Edwards Lifesciences Corporation
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$89.14 |
| 52 Week High | US$96.12 |
| 52 Week Low | US$60.57 |
| Beta | 1.1 |
| 1 Month Change | 3.72% |
| 3 Month Change | 3.53% |
| 1 Year Change | 1.38% |
| 3 Year Change | -5.37% |
| 5 Year Change | 57.88% |
| Change since IPO | 6,382.91% |
Noticias y actualizaciones recientes
Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
May 13
Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)
May 09When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?
Apr 29Recent updates
Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
May 13Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)
May 09When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?
Apr 29Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Apr 15Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear
Apr 01Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture
Feb 21Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)
Feb 14Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47
Feb 08Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly
Jan 28The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing
Jan 14Edwards Lifesciences: Undervalued With A Substantial Upside Potential
Jan 09Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up
Dec 31Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
Dec 17Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets
Oct 26Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Oct 23Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Oct 09Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value
Sep 26A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Sep 11Edwards Lifesciences: Rising Dominance In Structural Heart Disease
Aug 21Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jul 16Is It Too Late To Consider Buying Edwards Lifesciences Corporation (NYSE:EW)?
Jun 30Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value
Jun 15Edwards Lifesciences: Valuation Premium Earned, But Shares Are Not Cheap, Technicals Mixed
Jun 12Are Edwards Lifesciences Corporation (NYSE:EW) Investors Paying Above The Intrinsic Value?
May 31Edwards Lifesciences (NYSE:EW) Has A Rock Solid Balance Sheet
Apr 03What Is Edwards Lifesciences Corporation's (NYSE:EW) Share Price Doing?
Mar 22Investors Shouldn't Overlook The Favourable Returns On Capital At Edwards Lifesciences (NYSE:EW)
Mar 10Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
Feb 26Edwards Lifesciences downgraded to market perform at Raymond James on growth challenges
Feb 06Edwards Lifesciences slips as Piper downgrades on challenging setup
Jan 30Edwards Lifesciences: Short-Term Growth Worries Have Created An Opportunity
Jan 18Edwards Lifesciences: Catalysts For 2023 And Beyond
Dec 30Is Edwards Lifesciences (NYSE:EW) A Risky Investment?
Dec 28Is It Too Late To Consider Buying Edwards Lifesciences Corporation (NYSE:EW)?
Dec 16Rentabilidad de los accionistas
| EW | US Medical Equipment | Mercado US | |
|---|---|---|---|
| 7D | 2.8% | 1.6% | 1.7% |
| 1Y | 1.4% | 1.8% | 26.3% |
Rentabilidad vs. Industria: EW igualó a la industria US Medical Equipment, que obtuvo un rendimiento del 2% el año pasado.
Rentabilidad vs. Mercado: EW obtuvo unos resultados inferiores a los del mercado US, que fue del 24.9% el año pasado.
Volatilidad de los precios
| EW volatility | |
|---|---|
| EW Average Weekly Movement | 3.6% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Precio estable de las acciones: EW no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de EW (5%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1958 | 19,800 | Bernard Zovighian | www.edwards.com |
Edwards Lifesciences Corporation suministra productos y tecnologías para cardiopatías estructurales y monitorización de cuidados críticos en Estados Unidos, Europa, Japón e internacionalmente. Ofrece productos de sustitución valvular cardíaca transcatéter para la sustitución mínimamente invasiva de válvulas cardíacas aórticas bajo el sistema de válvulas de la familia Edwards SAPIEN; y productos de reparación y sustitución valvular cardíaca transcatéter para tratar enfermedades de las válvulas mitral y tricúspide bajo los nombres PASCAL PRECISION y Cardioband. La empresa también ofrece soluciones cardíacas estructurales quirúrgicas, como la válvula aórtica quirúrgica con el nombre INSPIRIS; la válvula aórtica INSPIRIS RESILLA, que ofrece la tecnología tisular RESILIA y VFit; KONECT RESILIA, un conducto de válvulas tisulares premontadas para procedimientos combinados complejos; y la válvula MITRIS RESILIA.
Resumen de fundamentos de Edwards Lifesciences Corporation
| Estadísticas fundamentales de EW | |
|---|---|
| Capitalización bursátil | US$53.72b |
| Beneficios(TTM) | US$1.41b |
| Ingresos (TTM) | US$6.14b |
38.0x
Ratio precio-beneficio (PE)8.7x
Ratio precio-ventas (PS)¿Está EW sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de EW | |
|---|---|
| Ingresos | US$6.14b |
| Coste de los ingresos | US$1.44b |
| Beneficio bruto | US$4.71b |
| Otros gastos | US$3.29b |
| Beneficios | US$1.41b |
Últimos beneficios comunicados
Mar 31, 2024
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 2.35 |
| Margen bruto | 76.63% |
| Margen de beneficio neto | 23.01% |
| Ratio deuda/patrimonio | 8.3% |
¿Cómo se ha desempeñado EW a largo plazo?
Ver rendimiento histórico y comparativa